Innovative antiviral defense with new CRISPR tool

2024-04-12

siRNA寡核苷酸

The rise of RNA viruses like SARS-CoV-2 highlights the need for new ways to fight them. RNA-targeting tools like CRISPR/Cas13 are powerful but inefficient in the cytoplasm of cells, where many RNA viruses replicate. Scientists have devised a solution: Cas13d-NCS. This new molecular tool allows CRISPR RNA molecules that are located within the nucleus of a cell to move to the cytoplasm, making it highly effective at neutralizing RNA viruses. This advancement opens doors for precision medicine and proactive viral defense strategies. The rise of RNA viruses like SARS-CoV-2 highlights the need for new ways to fight them. RNA-targeting tools like CRISPR/Cas13 are powerful but inefficient in the cytoplasm of cells, where many RNA viruses replicate. Scientists from Helmholtz Munich and the Technical University of Munich (TUM) have devised a solution: Cas13d-NCS. This new molecular tool allows CRISPR RNA molecules that are located within the nucleus of a cell to move to the cytoplasm, making it highly effective at neutralizing RNA viruses. This advancement opens doors for precision medicine and proactive viral defense strategies. The findings were published in Cell Discovery. As the world prepares for future and ongoing global health threats from RNA viruses such as the SARS-CoV-2 pandemic, breakthrough advances in antiviral development are becoming a critical weapon in the fight against these infectious diseases. At the heart of this innovation is the exploration of CRISPR/Cas13 systems, which are known for their programmable capabilities to manipulate RNAs and have become indispensable tools for various RNA targeting applications. However, a significant obstacle has hampered the effectiveness of Cas13d: its restriction to the nucleus of mammalian cells. This drastically limited its utility in cytosolic applications, such as programmable antiviral therapies. A Potent Antiviral Solution A scientific team working with Prof. Wolfgang Wurst, Dr. Christoph Gruber and Dr. Florian Giesert (Institute of Developmental Genetics at Helmholtz Munich and Chair of Developmental Genetics at TUM), which intensively collaborated with the teams of Dr. Gregor Ebert (Institute of Virology at Helmholtz Munich and at TUM) and of Prof. Andreas Pichlmair (Institute of Virology at TUM), successfully overcame this challenge associated with the cytosolic inactivity of Cas13d. Through careful screening and optimization, the researchers developed a transformative solution: Cas13d-NCS, a novel system capable of transferring nuclear crRNAs into the cytosol. crRNAs, or CRISPR RNAs, are short RNA molecules that guide the CRISPR-Cas complex to specific target sequences for precise modifications. In the cytosol, the protein/crRNA complex targets complementary RNAs and degrades them with unprecedented precision. With remarkable efficiency, Cas13d-NCS outperforms its predecessors in degrading mRNA targets and neutralizing self-replicating RNA, including replicating sequences of Venezuelan equine encephalitis (VEE) RNA virus and several variants of SARS-CoV-2, unlocking the full potential of Cas13d as a programmable antiviral-tool. Redefining the Landscape of RNA Virus Therapeutics This important achievement represents a significant step towards combating pandemics and strengthening defenses against future outbreaks. The impact of the study goes beyond traditional antiviral strategies and CRISPR systems and ushers in a new era of precision medicine by enabling the strategic manipulation of subcellular localization of CRISPR-based interventions. "This breakthrough in antiviral development with Cas13d-NCS marks a pivotal moment in our ongoing battle against RNA viruses," says Prof. Wolfgang Wurst, coordinator of the study. "This achievement showcases the power of collaborative innovation and human ingenuity in our quest for a healthier and more resilient world."

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构